BANG-BIN CHEN2020-08-122020-08-1220172167-4825https://scholars.lib.ntu.edu.tw/handle/123456789/511472Purpose of Review: PET-MRI is a novel imaging modality which can non-invasively provide both morphological and functional information about benign and malignant lesions. In this article, recent updates in the applications of PET-MRI in pancreatic and renal cancers are reviewed. Recent Findings: Multiparametric imaging has raised great interest in the oncology field by revealing various functional characteristics within tumors. For example, we can quantify tumor perfusion by dynamic contrast-enhanced MRI or arterial spin labeling MRI, tumor cellularity by diffusion-weighted image, tumor metabolites by MR spectroscopy, tumor metabolism by FDG-PET, and tumor heterogeneity by radiomics. Recent studies have demonstrated that these imaging biomarkers were correlated with tumor aggressiveness, treatment response, and prognosis. Summary: Combination of these imaging biomarkers from “one-stop shop” PET-MRI has great potential to more accurately characterize and monitor tumor behavior in the clinic to deliver individualized treatment plans. ? 2017, Springer Science+Business Media New York.Imaging biomarkers; Oncology; Pancreatic cancer; PET-MRI; Renal cancer[SDGs]SDG3deoxyhemoglobin; everolimus; hypoxia inducible factor 1alpha; Ki 67 antigen; protein tyrosine kinase inhibitor; vasculotropin; arterial spin labeling; cancer prognosis; cancer staging; chronic pancreatitis; computer assisted tomography; diffusion weighted imaging; fractional anisotropy; functional magnetic resonance imaging; glycolysis; human; kidney cancer; kidney metastasis; nuclear magnetic resonance imaging; nuclear magnetic resonance spectroscopy; overall survival; pancreas adenocarcinoma; pancreas cancer; positron emission tomography; priority journal; recurrence free survival; Review; sensitivity and specificity; tumor hypoxia; tumor volumereview10.1007/s40134-017-0229-52-s2.0-85062755217